| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2015: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
In this study, the rapamycin treatment significantly improved not only locomotor function, but also mechanical and thermal hypersensitivity in the hindpaws after SCI. In an immunohistochemical analysis, activation of microglia in the injured spinal cord was significantly decreased in the rapamycin-treated mice. In addition, the expressions of inflammatory cytokines in the injured site was significantly attenuated by rapamycin treatment. These results indicated rapamycin administration in acute phase reduced inflammation and secondary neural tissue damage in the injured site and attenuated the locomotor impairment and the development of neuropathic pain after SCI. The present study demonstrated that rapamycin has significant therapeutic potential for SCI. We have presented these data in several academic meetings in Japan and other countries. We also submitted the results of this study to an international scientific journal.
|
